Skip to main content

Table 4 LS mean of changes from baseline in FACT-B TOI with 95 % CIs (final analysis set)

From: Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study

  

Final analysis set (N = 486)

  

LS Mean

95 % CI

P value

Visit

6 months

4.04

1.64–6.43

–

 

12 months

7.10

4.57–9.63

–

 

18 months

6.54

3.84–9.25

–

 

24 months

8.51

5.75–11.27

–

 

6–12 months

−3.06

−4.06 to −2.06

<.0001

 

6–18 months

−2.50

−3.83 to −1.17

.0002

 

6–24 months

−4.48

−5.96 to −2.99

<.0001

 

12–18 months

0.56

−0.59 to 1.70

.3405

 

12–24 months

−1.41

−2.78 to −0.05

.0422

 

18–24 months

−1.97

−2.92 to −1.02

<.0001

Prior chemotherapies

Yes

10.99

8.20–13.77

–

 

No

2.11

−0.69 to 4.90

–

 

Yes–No

8.88

6.36–11.40

<.0001

Age group

>60 years

8.04

5.04–11.05

–

 

≤60 years

5.05

2.44–7.66

–

 

>60 to ≤60 years

2.99

0.37–5.61

.0256

Mastectomy

Yes

7.63

5.88–9.38

–

 

No

5.46

0.90–10.03

–

 

Yes–No

2.17

−2.63 to 6.97

.3752

Axillary lymph-node dissection

Yes

4.77

2.00–7.55

–

 

No

8.32

5.22–11.43

–

 

Yes–No

−3.55

−6.68 to −0.41

.0268

  1. CI confidence interval, FACT-B Functional Assessment of Cancer Therapy-Breast, LS least squares, TOI trial outcome index